Akebia Therapeutics (STU:AX9) Other Current Liabilities: €102.3 Mil (As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
46 GF Score
Price €1.13
GF Value €1.12
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Other Current Liabilities?

Akebia Therapeutics STU:AX9 +4.31% 46 Other Current Liabilities is €102.3 Mil as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 46/100 and a GF Value™ of €1.12 (Fairly Valued). The stock has 5 warning signs investors should review.

Akebia Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was €102.3 Mil.

Akebia Therapeutics's quarterly other current liabilities increased from Sep. 2025 (€34.2 Mil) to Dec. 2025 (€92.1 Mil) and increased from Dec. 2025 (€92.1 Mil) to Mar. 2026 (€102.3 Mil).

Akebia Therapeutics's annual other current liabilities declined from Dec. 2023 (€37.8 Mil) to Dec. 2024 (€34.7 Mil) but then increased from Dec. 2024 (€34.7 Mil) to Dec. 2025 (€92.1 Mil).

Akebia Therapeutics Other Current Liabilities Related Terms

Akebia Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Other Current Liabilities Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.60 49.59 37.76 34.70 92.08

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.84 30.97 34.21 92.08 102.33
STU:AX9
46GF Score
Akebia Therapeutics Inc STU:AX9
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €102.3 Mil mean?
Akebia Therapeutics (STU:AX9) has a Other Current Liabilities of €102.3 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Akebia Therapeutics.
Is Akebia Therapeutics' Other Current Liabilities too high?
Akebia Therapeutics' current Other Current Liabilities is €102.3 Mil. Overall, Akebia Therapeutics has a GF Score™ of 46/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Other Current Liabilities compare to TKNO and ORGO?
Akebia Therapeutics' Other Current Liabilities of €102.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Akebia Therapeutics. Akebia Therapeutics's current Other Current Liabilities is €102.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.13 — trading 0.5% above its estimated fair value. The current Other Current Liabilities is €102.3 Mil. Akebia Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Other Current Liabilities is €102.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.13 is trading 0.5% above its estimated GF Value™ of €1.12. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Other Current Liabilities: €102.3 Mil
  • GF Value™: €1.12 vs. price of €1.13 (0.5% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
46GF Score

Get the complete analysis for STU:AX9

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.13
Price
€1.12
GF Value